VERASTEM INC (VSTM) Stock News

USA - Nasdaq - NASDAQ:VSTM - US92337C2035 - Common Stock

10.41 USD

-0.19 (-1.79%)

Last: 12/5/2025, 2:18:10 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VSTM Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Verastem Oncology

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

21 days ago - By: Benzinga - Mentions: AVXL TSSI SEI RCAT ...

Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session

21 days ago - By: Zacks Investment Research - Mentions: EXAS GH TEM

TEM Continues to Strengthen Its Genomics Leadership With New Products

21 days ago - By: Benzinga - Mentions: OMER MLSS ICU CDTX ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

22 days ago - By: Verastem Oncology

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

a month ago - By: Zacks Investment Research

Verastem (VSTM) Upgraded to Buy: Here's Why

a month ago - By: Stocktwits

News Image

Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects

22 days ago - By: Verastem Oncology

Verastem Oncology Announces Proposed Public Offering of Common Stock

a month ago - By: Verastem Oncology

Verastem Oncology to Present at Upcoming Investor Conferences

a month ago - By: Zacks Investment Research - Mentions: ARVN

Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates

a month ago - By: Verastem Oncology

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

a month ago - By: Verastem Oncology

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

a month ago - By: Zacks Investment Research

Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

a month ago - By: Verastem Oncology

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

2 months ago - By: Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice

2 months ago - By: Zacks Investment Research

Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet

2 months ago - By: Verastem Oncology

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

2 months ago - By: Verastem Oncology

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Verastem Oncology

Verastem Oncology to Present at Upcoming Investor Conferences

4 months ago - By: Yahoo Finance

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

4 months ago - By: Verastem Oncology

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

4 months ago - By: Zacks Investment Research - Mentions: KMDA

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Verastem Oncology

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

4 months ago - By: Zacks Investment Research - Mentions: GOSS

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Verastem Oncology

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

4 months ago - By: Verastem Oncology

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

5 months ago - By: Verastem Oncology

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

5 months ago - By: FN Media Group LLC - Mentions: ONCY ONC.CA MBIO CRDF ...

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

5 months ago - By: Verastem Oncology

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Verastem Oncology

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

5 months ago - By: Verastem Oncology

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors